Related Experiment Video
Updated: Apr 8, 2026
08:14
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
16.3K
Serum cripto-1 as a clinical marker for lung cancer
Chun-Hua Xu1,2, Lan Cao2, Ying Wei2
1Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing, Jiangsu - PR China.
The International Journal of Biological Markers
|June 26, 2015
Summary
Serum Cripto-1 (CR-1) is elevated in lung cancer patients and correlates with disease progression and poorer survival in non-small cell lung cancer (NSCLC). This suggests CR-1 is a valuable biomarker for NSCLC diagnosis and prognosis.
Area of Science:
- Oncology
- Biomarkers
- Molecular Biology
Background:
- Cripto-1 (CR-1) is implicated in tumor angiogenesis alongside vascular endothelial growth factor (VEGF).
- Elevated CR-1 expression is observed in lung cancer tissues.
Purpose of the Study:
- To investigate the diagnostic and prognostic value of serum CR-1 and VEGF in lung cancer patients.
- To correlate serum CR-1 levels with non-small cell lung cancer (NSCLC) stage, metastasis, and overall survival.
Main Methods:
- Serum CR-1 and VEGF concentrations were measured in 156 lung cancer patients and 60 healthy volunteers using enzyme-linked immunosorbent assay (ELISA).
- Statistical analyses were performed to compare levels between groups and correlate with clinical parameters.
Main Results:
- Lung cancer patients exhibited significantly higher serum CR-1 and VEGF levels compared to healthy controls.
- Serum CR-1 levels increased with NSCLC stage progression and were higher in patients with distant metastasis.
- Lower serum CR-1 levels (<1.54 ng/mL) were associated with a better overall survival rate in NSCLC patients.
Conclusions:
- Serum CR-1 serves as a potential diagnostic marker for lung cancer.
- Serum CR-1 is a valuable prognostic indicator for NSCLC, correlating with survival outcomes.
